This inventor holds 4 USPTO granted patents and 10 published patent applications and 2 EPO patents. Top assignee: Baylor College of Medicine. Active years: 2016-2026.
Company Filing History:
Years Active: 2016-2026
Title: Nabil M Ahmed: Innovator in Targeted Delivery and Cancer Immunotherapy
Introduction
Nabil M Ahmed is a prominent inventor based in Houston, Texas, known for his significant contributions to the fields of targeted delivery and cancer immunotherapy. With a total of three patents to his name, Ahmed has made strides in developing innovative methods and compositions that enhance therapeutic interventions.
Latest Patents
One of Ahmed's latest patents is titled "Platform for Enhanced Targeted Delivery." This invention focuses on methods and compositions for delivering therapeutic, diagnostic, or interventional moieties, including complex and simple entities such as biologies. The methods utilize targeted delivery by employing at least one ALCAM-binding moiety on the therapeutic moiety to be delivered. In specific cases, the ALCAM-binding moiety is present in multiple iterations, enhancing the effectiveness of the delivery system.
Another notable patent is "Universal Immune Cells for Cancer Immunotherapy." This invention encompasses adoptive immunotherapy related to cells expressing multiple chimeric antigen receptors (CARs). In particular embodiments, T cells express a HER2-specific CAR, an IL13 Rα2-specific CAR, and an EphA2-specific CAR, which are utilized for cancer treatment, including glioblastoma.
Career Highlights
Nabil M Ahmed is affiliated with Baylor College of Medicine, where he continues to advance his research and innovations. His work has garnered attention for its potential impact on cancer treatment and targeted delivery systems.
Collaborations
Ahmed collaborates with notable colleagues, including Kristen Fousek and Malcolm K Brenner, who contribute to his research endeavors and innovations.
Conclusion
Nabil M Ahmed's work exemplifies the intersection of innovation and healthcare, particularly in the realms of targeted delivery and cancer immunotherapy. His patents reflect a commitment to advancing medical science and improving patient outcomes.